This is the authors' abstract. We don't add key points for this paper.
This study aimed to compare the 9-month efficacy and safety of paliperidone palmitate 1-monthly injection (PP1M) versus oral paliperidone extended-release (ER) tablets in patients with stable schizophrenia (SCZ). A single-center randomized controlled trial was conducted, enrolling 119 adult outpatients (mean age 46.03 years) diagnosed with SCZ (DSM-5 criteria), randomized to PP1M (n = 60) or ER (n = 59). The primary outcome was change in Positive and Negative Syndrome Scale (PANSS) total score, with secondary outcomes including Clinical Global Impression-Severity (CGIS) and Treatment Emergent Symptom Scale (TESS) scores. No statistically significant differences in PANSS total score improvements were observed between groups at 3, 6, and 9 months (P > 0.05). PP1M demonstrated transient superiority in CGI-S reduction at 3 and 6 months (mean difference: -0.31 and - 0.45, respectively; P < 0.05), but this difference dissipated by month 9. No significant differences in tolerability, as measured by TESS scores, were found between groups, with no significant differences in adverse events across follow-up periods. PP1M showed numerically greater (though nonsignificant) improvements in negative symptoms, suggesting potential subtle benefits. In conclusion, this study did not detect significant differences in long-term efficacy or safety between PP1M and ER in stable SCZ patients. While PP1M provided early CGI-S advantages likely attributable to adherence optimization, no inherent pharmacodynamic superiority was observed. These findings support PP1M as a pragmatic option for adherence-challenged patients, emphasizing individualized treatment selection based on preferences and feasibility.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: